ZOVIRAX RESISTANCE NOT CLINICALLY SIGNIFICANT, BURROUGHS WELLCOME
This article was originally published in The Tan Sheet
Executive Summary
ZOVIRAX RESISTANCE NOT CLINICALLY SIGNIFICANT, BURROUGHS WELLCOME research scientist Jack Hill suggested at a May 19 FDA public hearing on the company's Rx-to-OTC switch application for Zovirax (acyclovir). "We believe that acyclovir-resistant viruses ...cause little if any clinically significant diseases in people with healthy immune systems," Hill said.